Adipokines and Their Receptors: Potential New Targets in Cardiovascular Diseases

References

• González-Juanatey JR , Lago PazF, EirasS, Teijeira-FernándezE. Adipocitocinas como nuevos marcadores de la enfermedad cardiovascular. Perspectivas fisiopatológicas y clínicas. Revista Española de Cardiología62 (Suppl. 2), 9–16 (2009).
   PubMedGoogle Scholar
• Horwich TB , FonarowGC, HamiltonMA, MaclellanWR, WooMA, TillischJH. The relationship between obesity and mortality in patients with heart failure. J. Am. Coll. Cardiol.38 (3), 789–795 (2001).
   PubMed Web of Science ®Google Scholar
• Goncalves N , Roncon-AlbuquerqueRJr, OliveiraM, Quina-RodriguesC, LourencoAP, Leite-MoreiraAF. A high-calorie diet attenuates cachexia and adipose tissue inflammation in monocrotaline-induced pulmonary hypertensive rats. Rev. Port. Cardiol.29 (3), 391–400 (2010).
   PubMedGoogle Scholar
• Lavie CJ , MilaniRV, VenturaHO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J. Am. Coll. Cardiol.53 (21), 1925–1932 (2009).
   PubMed Web of Science ®Google Scholar
• Alpert MA , AgrawalH, AggarwalK, KumarSA, KumarA. Heart failure and obesity in adults: pathophysiology, clinical manifestations and management. Curr. Heart Fail. Rep11 (2), 156–165 (2014).
   PubMedGoogle Scholar
• Wende AR , YoungME. APpEaLINg therapeutic target for obesity cardiomyopathy?J. Mol. Cell Cardiol.63, 165–168 (2013).
   PubMed Web of Science ®Google Scholar
• Iozzo P . Myocardial, perivascular, and epicardial fat. Diabetes Care34 (Suppl. 2), S371–S379 (2011).
   PubMed Web of Science ®Google Scholar
• Yudkin JS , EringaE, StehouwerCD. “Vasocrine” signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet365 (9473), 1817–1820 (2005).
   PubMed Web of Science ®Google Scholar
• Iacobellis G , BarbaroG. The double role of epicardial adipose tissue as pro- and anti-inflammatory organ. Horm. Metab. Res.40 (7), 442–445 (2008).
   PubMed Web of Science ®Google Scholar
• Iacobellis G , WillensHJ. Echocardiographic epicardial fat: a review of research and clinical applications. J. Am. Soc. Echocardiogr.22 (12), 1311–1319; quiz 1417–1318 (2009).
   PubMed Web of Science ®Google Scholar
• Lavie CJ , AlpertMA, ArenaR, MehraMR, MilaniRV, VenturaHO. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail.1 (2), 93–102 (2013).
   PubMed Web of Science ®Google Scholar
• Oreopoulos A , PadwalR, Kalantar-ZadehK, FonarowGC, NorrisCM, McAlisterFA. Body mass index and mortality in heart failure: a meta-analysis. Am. Heart J.156 (1), 13–22 (2008).
   PubMed Web of Science ®Google Scholar
• O'dowd BF , HeiberM, ChanAet al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene136 (1–2), 355–360 (1993).
   PubMed Web of Science ®Google Scholar
• Tatemoto K , HosoyaM, HabataYet al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem. Biophys. Res. Commun.251 (2), 471–476 (1998).
   PubMed Web of Science ®Google Scholar
• Habata Y , FujiiR, HosoyaMet al. Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum. Biochim. Biophys. Acta1452 (1), 25–35 (1999).
   PubMed Web of Science ®Google Scholar
• Machura E , ZioraK, ZioraDet al. Serum apelin-12 level is elevated in schoolchildren with atopic asthma. Respir. Med.107 (2), 196–201 (2013).
   PubMed Web of Science ®Google Scholar
• Scimia MC , HurtadoC, RaySet al. APJ acts as a dual receptor in cardiac hypertrophy. Nature488 (7411), 394–398 (2012).
   PubMed Web of Science ®Google Scholar
• Chun HJ , AliZA, KojimaYet al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J. Clin. Invest.118 (10), 3343–3354 (2008).
   PubMed Web of Science ®Google Scholar
• Hosoya M , KawamataY, FukusumiSet al. Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J. Biol. Chem.275 (28), 21061–21067 (2000).
   PubMed Web of Science ®Google Scholar
• Kawamata Y , HabataY, FukusumiSet al. Molecular properties of apelin: tissue distribution and receptor binding. Biochim. Biophys. Acta1538 (2–3), 162–171 (2001).
   PubMed Web of Science ®Google Scholar
• Kleinz MJ , SkepperJN, DavenportAP. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul. Pept.126 (3), 233–240 (2005).
   PubMedGoogle Scholar
• Medhurst AD , JenningsCA, RobbinsMJet al. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J. NeuroChem.84 (5), 1162–1172 (2003).
   PubMed Web of Science ®Google Scholar
• O'carroll AM , SelbyTL, PalkovitsM, LolaitSJ. Distribution of mRNA encoding B78/apj, the rat homologue of the human APJ receptor, and its endogenous ligand apelin in brain and peripheral tissues. Biochim. Biophys. Acta1492 (1), 72–80 (2000).
   PubMedGoogle Scholar
• Boucher J , MasriB, DaviaudDet al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology146 (4), 1764–1771 (2005).
   PubMed Web of Science ®Google Scholar
• Ceylan-Isik AF , KandadiMR, XuXet al. Apelin administration ameliorates high fat diet-induced cardiac hypertrophy and contractile dysfunction. J. Mol. Cell Cardiol.63, 4–13 (2013).
   PubMed Web of Science ®Google Scholar
• Ba HJ , ChenHS, SuZet al. Associations between serum apelin-12 levels and obesity-related markers in Chinese children. PLoS One9 (1), e86577 (2014).
   PubMed Web of Science ®Google Scholar
• Falcao-PiRes I , Leite-MoreiraAF. Apelin: a novel neurohumoral modulator of the cardiovascular system. Pathophysiologic importance and potential use as a therapeutic target. Rev. Port. Cardiol.24 (10), 1263–1276 (2005).
   PubMedGoogle Scholar
• Karadag S , OzturkS, GursuMet al. The relationship between apelin and cardiac parameters in patients on peritoneal dialysis: is there a new cardiac marker? BMC Nephrol 15 (1), 18 (2014).
   PubMedGoogle Scholar
• Falcao-PiRes I , Ladeiras-LopesR, Leite-MoreiraAF. The apelinergic system: a promising therapeutic target. Expert Opin. Ther. Targets14 (6), 633–645 (2010).
   PubMed Web of Science ®Google Scholar
• Foldes G , HorkayF, SzokodiIet al. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem. Biophys. Res. Commun.308 (3), 480–485 (2003).
   PubMed Web of Science ®Google Scholar
• Ladeiras-Lopes R , Ferreira-MartinsJ, Leite-MoreiraAF. The apelinergic system: the role played in human physiology and pathology and potential therapeutic applications. Arq. Bras. Cardiol.90 (5), 343–349 (2008).
   PubMed Web of Science ®Google Scholar
• Ishida J , HashimotoT, HashimotoYet al. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressurein vivo. J. Biol. Chem.279 (25), 26274–26279 (2004).
   PubMed Web of Science ®Google Scholar
• Katugampola SD , MaguireJJ, MatthewsonSR, DavenportAP. [(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br. J. Pharmacol.132 (6), 1255–1260 (2001).
   PubMed Web of Science ®Google Scholar
• Andersen CU , HilbergO, MellemkjaerS, Nielsen-KudskJE, SimonsenU. Apelin and pulmonary hypertension. Pulm. Circ.1 (3), 334–346 (2011).
   PubMedGoogle Scholar
• Zhang J , RenCX, QiYFet al. Exercise training promotes expression of apelin and APJ of cardiovascular tissues in spontaneously hypertensive rats. Life Sci.79 (12), 1153–1159 (2006).
   PubMed Web of Science ®Google Scholar
• Barnes GD , AlamS, CarterGet al. Sustained cardiovascular actions of APJ agonism during renin-angiotensin system activation and in patients with heart failure. Circ. Heart Fail.6 (3), 482–491 (2013).
   PubMed Web of Science ®Google Scholar
• Vickers C , HalesP, KaushikVet al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem.277 (17), 14838–14843 (2002).
   PubMed Web of Science ®Google Scholar
• Sato T , SuzukiT, WatanabeHet al. Apelin is a positive regulator of ACE2 in failing hearts. J. Clin. Invest.123 (12), 5203–5211 (2013).
   PubMed Web of Science ®Google Scholar
• Kazemi-Bajestani SM , PatelVB, WangW, OuditGY. Targeting the ACE2 and apelin pathways are novel therapies for heart failure: opportunities and challenges. Cardiol. Res. Pract.2012, 823193 (2012).
   PubMedGoogle Scholar
• Reaux A , De MotaN, SkultetyovaIet al. Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain. J. NeuroChem.77 (4), 1085–1096 (2001).
   PubMed Web of Science ®Google Scholar
• Szokodi I , TaviP, FoldesGet al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ. Res.91 (5), 434–440 (2002).
   PubMed Web of Science ®Google Scholar
• Ashley EA , PowersJ, ChenMet al. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc. Res.65 (1), 73–82 (2005).
   PubMed Web of Science ®Google Scholar
• Dai T , Ramirez-CorreaG, GaoWD. Apelin increases contractility in failing cardiac muscle. Eur. J. Pharmacol.553 (1–3), 222–228 (2006).
   PubMed Web of Science ®Google Scholar
• Jia YX , PanCS, ZhangJet al. Apelin protects myocardial injury induced by isoproterenol in rats. Regul. Pept.133 (1–3), 147–154 (2006).
   PubMedGoogle Scholar
• Falcao-PiRes I , GoncalvesN, Henriques-CoelhoT, Moreira-GoncalvesD, Roncon-AlbuquerqueRJr, Leite-MoreiraAF. Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension. Am. J. Physiol. Heart Circ. Physiol.296 (6), H2007–H2014 (2009).
   PubMed Web of Science ®Google Scholar
• Chen MM , AshleyEA, DengDXet al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation108 (12), 1432–1439 (2003).
   PubMed Web of Science ®Google Scholar
• Chong KS , GardnerRS, MortonJJ, AshleyEA, McdonaghTA. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur. J. Heart Fail.8 (4), 355–360 (2006).
   PubMed Web of Science ®Google Scholar
• Goetze JP , RehfeldJF, CarlsenJet al. Apelin: a new plasma marker of cardiopulmonary disease. Regul. Pept.133 (1–3), 134–138 (2006).
   PubMedGoogle Scholar
• Miettinen KH , MaggaJ, VuolteenahoOet al. Utility of plasma apelin and other indices of cardiac dysfunction in the clinical assessment of patients with dilated cardiomyopathy. Regul. Pept.140 (3), 178–184 (2007).
   PubMedGoogle Scholar
• Ashley EA , ChenM, QuertermousTet al. Diagnostic markers and pharmacological targets in heart failure and related reagents and methods of use thereof US20050152836 A1(US 10/850,941), (2005). www.google.com/patents/WO2005029066A2?cl=en.
   Google Scholar
• Falcao-Pires I , GoncalvesN, GavinaCet al. Correlation between plasma levels of apelin and myocardial hypertrophy in rats and humans: possible target for treatment? Expert Opin. Ther. Targets 14 (3), 231–241 (2010).
   PubMed Web of Science ®Google Scholar
• Ronkainen VP , RonkainenJJ, HanninenSLet al. Hypoxia inducible factor regulates the cardiac expression and secretion of apelin. FASEB J.21 (8), 1821–1830 (2007).
   PubMed Web of Science ®Google Scholar
• Pchejetski D , FoussalC, AlfaranoCet al. Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1. Eur. Heart J.33 (18), 2360–2369 (2012).
   PubMed Web of Science ®Google Scholar
• Simpkin JC , YellonDM, DavidsonSM, LimSY, WynneAM, SmithCC. Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury. Basic Res. Cardiol.102 (6), 518–528 (2007).
   PubMed Web of Science ®Google Scholar
• Tao J , ZhuW, LiYet al. Apelin-13 protects the heart against ischemia-reperfusion injury through inhibition of ER-dependent apoptotic pathways in a time-dependent fashion. Am. J. Physiol. Heart Circ. Physiol.301 (4), H1471–H1486 (2011).
   PubMed Web of Science ®Google Scholar
• Zeng XJ , ZhangLK, WangHX, LuLQ, MaLQ, TangCS. Apelin protects heart against ischemia/reperfusion injury in rat. Peptides30 (6), 1144–1152 (2009).
   PubMed Web of Science ®Google Scholar
• Arita Y , KiharaS, OuchiNet al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun.257 (1), 79–83 (1999).
   PubMed Web of Science ®Google Scholar
• Mattu HS , RandevaHS. Role of adipokines in cardiovascular disease. J. Endocrinol.216 (1), T17–36 (2013).
   PubMed Web of Science ®Google Scholar
• Fruebis J , TsaoTS, JavorschiSet al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl Acad. Sci. USA98 (4), 2005–2010 (2001).
   PubMed Web of Science ®Google Scholar
• Tsao TS , MurreyHE, HugC, LeeDH, LodishHF. Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J. Biol. Chem.277 (33), 29359–29362 (2002).
   PubMed Web of Science ®Google Scholar
• Tsao TS , TomasE, MurreyHEet al. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. J. Biol. Chem.278 (50), 50810–50817 (2003).
   PubMed Web of Science ®Google Scholar
• Pajvani UB , DuX, CombsTPet al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J. Biol. Chem.278 (11), 9073–9085 (2003).
   PubMed Web of Science ®Google Scholar
• Yamauchi T , KamonJ, WakiHet al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J. Biol. Chem.278 (4), 2461–2468 (2003).
   PubMed Web of Science ®Google Scholar
• Hug C , WangJ, AhmadNS, BoganJS, TsaoTS, LodishHF. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc. Natl Acad. Sci. USA101 (28), 10308–10313 (2004).
   PubMed Web of Science ®Google Scholar
• Ding G , QinQ, HeNet al. Adiponectin and its receptors are expressed in adult ventricular cardiomyocytes and upregulated by activation of peroxisome proliferator-activated receptor gamma. J. Mol. Cell Cardiol.43 (1), 73–84 (2007).
   PubMed Web of Science ®Google Scholar
• Fujioka D , KawabataK, SaitoYet al. Role of adiponectin receptors in endothelin-induced cellular hypertrophy in cultured cardiomyocytes and their expression in infarcted heart. Am. J. Physiol. Heart Circ. Physiol.290 (6), H2409–H2416 (2006).
   PubMed Web of Science ®Google Scholar
• Pineiro R , IglesiasMJ, GallegoRet al. Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett579 (23), 5163–5169 (2005).
   PubMed Web of Science ®Google Scholar
• Van De Voorde J , PauwelsB, BoydensC, DecaluweK. Adipocytokines in relation to cardiovascular disease. Metabolism62 (11), 1513–1521 (2013).
   PubMed Web of Science ®Google Scholar
• Yamauchi T , KamonJ, WakiHet al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med.7 (8), 941–946 (2001).
   PubMed Web of Science ®Google Scholar
• Chow WS , CheungBM, TsoAWet al. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension49 (6), 1455–1461 (2007).
   PubMed Web of Science ®Google Scholar
• Shibata R , OuchiN, ItoMet al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat. Med.10 (12), 1384–1389 (2004).
   PubMed Web of Science ®Google Scholar
• Cnop M , HavelPJ, UtzschneiderKMet al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia46 (4), 459–469 (2003).
   PubMed Web of Science ®Google Scholar
• Falcao-PiRes I , Castro-ChavesP, Miranda-SilvaD, LourencoAP, Leite-MoreiraAF. Physiological, pathological and potential therapeutic roles of adipokines. Drug Discov. Today17 (15–16), 880–889 (2012).
   PubMed Web of Science ®Google Scholar
• Pilz S , MaerzW, WeihrauchGet al. Adiponectin serum concentrations in men with coronary artery disease: the LUdwigshafen RIsk and Cardiovascular Health (LURIC) study. Clin. Chim. Acta364 (1–2), 251–255 (2006).
   PubMed Web of Science ®Google Scholar
• Shimada K , MiyazakiT, DaidaH. Adiponectin and atherosclerotic disease. Clin. Chim. Acta344 (1–2), 1–12 (2004).
   PubMed Web of Science ®Google Scholar
• Ouchi N , KiharaS, AritaYet al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation100 (25), 2473–2476 (1999).
   PubMed Web of Science ®Google Scholar
• Ouchi N , KiharaS, AritaYet al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation103 (8), 1057–1063 (2001).
   PubMed Web of Science ®Google Scholar
• Ouedraogo R , GongY, BerzinsBet al. Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J. Clin. Invest.117 (6), 1718–1726 (2007).
   PubMed Web of Science ®Google Scholar
• Bruun JM , LihnAS, VerdichCet al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am. J. Physiol. Endocrinol. Metab.285 (3), E527–E533 (2003).
   PubMed Web of Science ®Google Scholar
• Arita Y , KiharaS, OuchiNet al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation105 (24), 2893–2898 (2002).
   PubMed Web of Science ®Google Scholar
• Hopkins TA , OuchiN, ShibataR, WalshK. Adiponectin actions in the cardiovascular system. Cardiovasc. Res.74 (1), 11–18 (2007).
   PubMed Web of Science ®Google Scholar
• Kostopoulos CG , SpiroglouSG, VarakisJN, ApostolakisE, PapadakiHH. Adiponectin/T-cadherin and apelin/APJ expression in human arteries and periadventitial fat: implication of local adipokine signaling in atherosclerosis?Cardiovasc. Pathol.23 (3), 131–138 (2014).
   PubMed Web of Science ®Google Scholar
• Shibata R , IzumiyaY, SatoKet al. Adiponectin protects against the development of systolic dysfunction following myocardial infarction. J. Mol. Cell Cardiol.42 (6), 1065–1074 (2007).
   PubMed Web of Science ®Google Scholar
• Hong SJ , ParkCG, SeoHS, OhDJ, RoYM. Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index. Blood Press.13 (4), 236–242 (2004).
   PubMed Web of Science ®Google Scholar
• Takahashi T , YuF, SaegusaSet al. Impaired expression of cardiac adiponectin in leptin-deficient mice with viral myocarditis. Int. Heart J.47 (1), 107–123 (2006).
   PubMed Web of Science ®Google Scholar
• Eiras S , Teijeira-FernandezE, ShamagianLG, FernandezAL, Vazquez-BoqueteA, Gonzalez-JuanateyJR. Extension of coronary artery disease is associated with increased IL-6 and decreased adiponectin gene expression in epicardial adipose tissue. Cytokine43 (2), 174–180 (2008).
   PubMed Web of Science ®Google Scholar
• Teijeira-Fernandez E , EirasS, Grigorian-ShamagianL, FernandezA, AdrioB, Gonzalez-JuanateyJR. Epicardial adipose tissue expression of adiponectin is lower in patients with hypertension. J. Hum. Hypertens.22 (12), 856–863 (2008).
   PubMed Web of Science ®Google Scholar
• Ohashi K , KiharaS, OuchiNet al. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension47 (6), 1108–1116 (2006).
   PubMed Web of Science ®Google Scholar
• Tao L , GaoE, JiaoXet al. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation115 (11), 1408–1416 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang Y , ProencaR, MaffeiM, BaroneM, LeopoldL, FriedmanJM. Positional cloning of the mouse obese gene and its human homologue. Nature372 (6505), 425–432 (1994).
   PubMed Web of Science ®Google Scholar
• Wellhoener P , Fruehwald-SchultesB, KernWet al. Glucose metabolism raTher. than insulin is a main determinant of leptin secretion in humans. J. Clin. Endocrinol. Metab.85 (3), 1267–1271 (2000).
   PubMed Web of Science ®Google Scholar
• Saladin R , De VosP, Guerre-MilloMet al. Transient increase in obese gene expression after food intake or insulin administration. Nature377 (6549), 527–529 (1995).
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF , Escobar Del ReyF, Morreale De EscobarG. Thyroid hormones influence serum leptin concentrations in the rat. Endocrinology138 (10), 4485–4488 (1997).
   PubMed Web of Science ®Google Scholar
• Bornstein SR , LicinioJ, TauchnitzRet al. Plasma leptin levels are increased in survivors of acute sepsis: associated loss of diurnal rhythm, in cortisol and leptin secretion. J. Clin. Endocrinol. Metab.83 (1), 280–283 (1998).
   PubMed Web of Science ®Google Scholar
• Tartaglia LA , DembskiM, WengXet al. Identification and expression cloning of a leptin receptor, OB-R. Cell83 (7), 1263–1271 (1995).
   PubMed Web of Science ®Google Scholar
• Beltowski J . Leptin and atherosclerosis. Atherosclerosis189 (1), 47–60 (2006).
   PubMed Web of Science ®Google Scholar
• Oral EA , SimhaV, RuizEet al. Leptin-replacement therapy for lipodystrophy. N. Engl. J. Med.346 (8), 570–578 (2002).
   PubMed Web of Science ®Google Scholar
• Considine RV , SinhaMK, HeimanMLet al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med.334 (5), 292–295 (1996).
   PubMed Web of Science ®Google Scholar
• Myers MG Jr , HeymsfieldSB, HaftCet al. Challenges and opportunities of defining clinical leptin resistance. Cell Metab.15 (2), 150–156 (2012).
   PubMed Web of Science ®Google Scholar
• El-Haschimi K , PierrozDD, HilemanSM, BjorbaekC, FlierJS. Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J. Clin. Invest.105 (12), 1827–1832 (2000).
   PubMed Web of Science ®Google Scholar
• Karmazyn M , PurdhamDM, RajapurohitamV, ZeidanA. Leptin as a cardiac hypertrophic factor: a potential target for therapeutics. Trends Cardiovasc. Med.17 (6), 206–211 (2007).
   PubMed Web of Science ®Google Scholar
• Lago F , DieguezC, Gomez-ReinoJ, GualilloO. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev.18 (3–4), 313–325 (2007).
   PubMed Web of Science ®Google Scholar
• Quehenberger P , ExnerM, Sunder-PlassmannRet al. Leptin induces endothelin-1 in endothelial cells in vitro. Circ. Res.90 (6), 711–718 (2002).
   PubMed Web of Science ®Google Scholar
• Zeidan A , PurdhamDM, RajapurohitamV, JavadovS, ChakrabartiS, KarmazynM. Leptin induces vascular smooth muscle cell hypertrophy through angiotensin II- and endothelin-1-dependent mechanisms and mediates stretch-induced hypertrophy. J. Pharmacol. Exp. Ther.315 (3), 1075–1084 (2005).
   PubMed Web of Science ®Google Scholar
• Howard JK , LordGM, MatareseGet al. Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in ob/ob mice. J. Clin. Invest.104 (8), 1051–1059 (1999).
   PubMed Web of Science ®Google Scholar
• Reyes M , QuintanillaC, BurrowsR, BlancoE, CifuentesM, GahaganS. Obesity is associated with acute inflammation in a sample of adolescents. Pediatr. Diabetes doi:10.1111/pedi.12129 (2014) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Pan H , GuoJ, SuZ. Advances in understanding the interrelations between leptin resistance and obesity. Physiol. Behav.30, 157–169 (2014).
   Google Scholar
• Smith CC , MocanuMM, DavidsonSM, WynneAM, SimpkinJC, YellonDM. Leptin, the obesity-associated hormone, exhibits direct cardioprotective effects. Br. J. Pharmacol.149 (1), 5–13 (2006).
   PubMed Web of Science ®Google Scholar
• Shek EW , BrandsMW, HallJE. Chronic leptin infusion increases arterial pressure. Hypertension31 (1 Pt 2), 409–414 (1998).
   PubMed Web of Science ®Google Scholar
• Ozata M , OzdemirIC, LicinioJ. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J. Clin. Endocrinol. Metab.84 (10), 3686–3695 (1999).
   PubMed Web of Science ®Google Scholar
• Rodriguez A , FruhbeckG, Gomez-AmbrosiJet al. The inhibitory effect of leptin on angiotensin II-induced vasoconstriction is blunted in spontaneously hypertensive rats. J. Hypertens.24 (8), 1589–1597 (2006).
   PubMed Web of Science ®Google Scholar
• Hare JM , StamlerJS. NO/redox disequilibrium in the failing heart and cardiovascular system. J. Clin. Invest.115 (3), 509–517 (2005).
   PubMed Web of Science ®Google Scholar
• Dong F , ZhangX, RenJ. Leptin regulates cardiomyocyte contractile function through endothelin-1 receptor-NADPH oxidase pathway. Hypertension47 (2), 222–229 (2006).
   PubMed Web of Science ®Google Scholar
• Ren J , ZhuBH, RellingDP, EsbergLB, Ceylan-IsikAF. High-fat diet-induced obesity leads to resistance to leptin-induced cardiomyocyte contractile response. Obesity (Silver Spring)16 (11), 2417–2423 (2008).
   PubMed Web of Science ®Google Scholar
• Ricci E , SmallwoodS, ChouabeCet al. Electrophysiological characterization of left ventricular myocytes from obese Sprague-Dawley rat. Obesity (Silver Spring)14 (5), 778–786 (2006).
   PubMed Web of Science ®Google Scholar
• Madani S , De GirolamoS, MunozDM, LiRK, SweeneyG. Direct effects of leptin on size and extracellular matrix components of human pediatric ventricular myocytes. Cardiovasc. Res.69 (3), 716–725 (2006).
   PubMed Web of Science ®Google Scholar
• Steppan CM , BaileyST, BhatSet al. The hormone resistin links obesity to diabetes. Nature409 (6818), 307–312 (2001).
   PubMed Web of Science ®Google Scholar
• Barnes KM , MinerJL. Role of resistin in insulin sensitivity in rodents and humans. Curr. Protein Pept. Sci.10 (1), 96–107 (2009).
   PubMed Web of Science ®Google Scholar
• Kunnari A , UkkolaO, PaivansaloM, KesaniemiYA. High plasma resistin level is associated with enhanced highly sensitive C-reactive protein and leukocytes. J. Clin. Endocrinol. Metab.91 (7), 2755–2760 (2006).
   PubMed Web of Science ®Google Scholar
• Bokarewa M , NagaevI, DahlbergL, SmithU, TarkowskiA. Resistin, an adipokine with potent proinflammatory properties. J. Immunol.174 (9), 5789–5795 (2005).
   PubMed Web of Science ®Google Scholar
• Silswal N , SinghAK, ArunaB, MukhopadhyayS, GhoshS, EhteshamNZ. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem. Biophys. Res. Commun.334 (4), 1092–1101 (2005).
   PubMed Web of Science ®Google Scholar
• Calabro P , SamudioI, WillersonJT, YehET. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation110 (21), 3335–3340 (2004).
   PubMed Web of Science ®Google Scholar
• Mu H , OhashiR, YanSet al. Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc. Res.70 (1), 146–157 (2006).
   PubMed Web of Science ®Google Scholar
• Rae C , RobertsonSA, TaylorJM, GrahamA. Resistin induces lipolysis and re-esterification of triacylglycerol stores, and increases cholesteryl ester deposition, in human macrophages. FEBS Lett.581 (25), 4877–4883 (2007).
   PubMed Web of Science ®Google Scholar
• Calabro P , CirilloP, LimongelliGet al. Tissue factor is induced by resistin in human coronary artery endothelial cells by the NF-kB-dependent pathway. J. Vasc. Res.48 (1), 59–66 (2011).
   PubMed Web of Science ®Google Scholar
• Chen C , JiangJ, LuJMet al. Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Am. J. Physiol. Heart Circ. Physiol.299 (1), H193–H201 (2010).
   PubMed Web of Science ®Google Scholar
• Robertson SA , RaeCJ, GrahamA. Induction of angiogenesis by murine resistin: putative role of PI3-kinase and NO-dependent pathways. Regul. Pept.152 (1–3), 41–47 (2009).
   PubMedGoogle Scholar
• Chemaly ER , HadriL, ZhangSet al. Long-term in vivo resistin overexpression induces myocardial dysfunction and remodeling in rats. J. Mol. Cell Cardiol.51 (2), 144–155 (2011).
   PubMed Web of Science ®Google Scholar
• Lubos E , MessowCM, SchnabelRet al. Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. Atherosclerosis193 (1), 121–128 (2007).
   PubMed Web of Science ®Google Scholar
• Fukuhara A , MatsudaM, NishizawaMet al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science307 (5708), 426–430 (2005).
   PubMed Web of Science ®Google Scholar
• Samal B , SunY, StearnsG, XieC, SuggsS, McNieceI. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol. Cell Biol.14 (2), 1431–1437 (1994).
   PubMed Web of Science ®Google Scholar
• Rongvaux A , SheaRJ, MulksMHet al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur. J. Immunol.32 (11), 3225–3234 (2002).
   PubMed Web of Science ®Google Scholar
• Haider DG , HolzerG, SchallerGet al. The adipokine visfatin is markedly elevated in obese children. J. Pediatr. Gastroenterol. Nutr.43 (4), 548–549 (2006).
   PubMed Web of Science ®Google Scholar
• Haider DG , SchindlerK, SchallerG, PragerG, WolztM, LudvikB. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J. Clin. Endocrinol. Metab.91 (4), 1578–1581 (2006).
   PubMed Web of Science ®Google Scholar
• Retnakaran R , YounBS, LiuYet al. Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross-sectional study. Clin. Endocrinol. (Oxford)69 (6), 885–893 (2008).
   PubMed Web of Science ®Google Scholar
• Hausenloy DJ . Drug discovery possibilities from visfatin cardioprotection?Curr. Opin. Pharmacol.9 (2), 202–207 (2009).
   PubMed Web of Science ®Google Scholar
• Chan TF , ChenYL, LeeCHet al. Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. J. Soc. Gynecol. Investig.13 (5), 364–367 (2006).
   PubMedGoogle Scholar
• Pagano C , PilonC, OlivieriMet al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J. Clin. Endocrinol. Metab.91 (8), 3165–3170 (2006).
   PubMed Web of Science ®Google Scholar
• Adeghate E . Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr. Med. Chem.15 (18), 1851–1862 (2008).
   PubMed Web of Science ®Google Scholar
• Xie H , TangSY, LuoXHet al. Insulin-like effects of visfatin on human osteoblasts. Calcif. Tissue Int.80 (3), 201–210 (2007).
   PubMed Web of Science ®Google Scholar
• Dahl TB , YndestadA, SkjellandMet al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation115 (8), 972–980 (2007).
   PubMed Web of Science ®Google Scholar
• Takebayashi K , SuetsuguM, WakabayashiS, AsoY, InukaiT. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism56 (4), 451–458 (2007).
   PubMed Web of Science ®Google Scholar
• Adya R , TanBK, ChenJ, RandevaHS. Pre-B cell colony enhancing factor (PBEF)/visfatin induces secretion of MCP-1 in human endothelial cells: role in visfatin-induced angiogenesis. Atherosclerosis205 (1), 113–119 (2009).
   PubMed Web of Science ®Google Scholar
• Kim SR , BaeSK, ChoiKSet al. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem. Biophys. Res. Commun.357 (1), 150–156 (2007).
   PubMed Web of Science ®Google Scholar
• Park JW , KimWH, ShinSHet al. Visfatin exerts angiogenic effects on human umbilical vein endothelial cells through the mTOR signaling pathway. Biochim. Biophys. Acta1813 (5), 763–771 (2011).
   PubMed Web of Science ®Google Scholar
• Pillai VB , SundaresanNR, KimGet al. Nampt secreted from cardiomyocytes promotes development of cardiac hypertrophy and adverse ventricular remodeling. Am. J. Physiol. Heart Circ. Physiol.304 (3), H415–H426 (2013).
   PubMed Web of Science ®Google Scholar
• Yu XY , QiaoSB, GuanHS, LiuSW, MengXM. Effects of visfatin on proliferation and collagen synthesis in rat cardiac fibroblasts. Horm. Metab. Res.42 (7), 507–513 (2010).
   PubMed Web of Science ®Google Scholar
• Lim SY , DavidsonSM, ParamanathanAJ, SmithCC, YellonDM, HausenloyDJ. The novel adipocytokine visfatin exerts direct cardioprotective effects. J. Cell Mol. Med.12 (4), 1395–1403 (2008).
   PubMed Web of Science ®Google Scholar
• Hertzel AV , BernlohrDA. The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function. Trends Endocrinol. Metab.11 (5), 175–180 (2000).
   PubMed Web of Science ®Google Scholar
• Agra RM , Fernandez-TrasancosA, SierraJ, Gonzalez-JuanateyJR, EirasS. Differential association of S100A9, an inflammatory marker, and p53, a cell cycle marker, expression with epicardial adipocyte size in patients with cardiovascular disease. Inflammation37 (5), 1504–1512 (2014).
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS , JohnsonRS, DistelRJ, EllisR, PapaioannouVE, SpiegelmanBM. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science274 (5291), 1377–1379 (1996).
   PubMed Web of Science ®Google Scholar
• Uysal KT , SchejaL, WiesbrockSM, Bonner-WeirS, HotamisligilGS. Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology141 (9), 3388–3396 (2000).
   PubMed Web of Science ®Google Scholar
• Furuhashi M , TuncmanG, GorgunCZet al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature447 (7147), 959–965 (2007).
   PubMed Web of Science ®Google Scholar
• Tuncman G , ErbayE, HomXet al. A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc. Natl Acad. Sci. USA103 (18), 6970–6975 (2006).
   PubMed Web of Science ®Google Scholar
• Lamounier-Zepter V , LookC, AlvarezJet al. Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: a new link between obesity and heart disease. Circ. Res.105 (4), 326–334 (2009).
   PubMed Web of Science ®Google Scholar
• Donato R , CannonBR, SorciGet al. Functions of S100 proteins. Curr. Mol. Med.13 (1), 24–57 (2013).
   PubMed Web of Science ®Google Scholar
• Tsoporis JN , MarksA, HaddadA, DawoodF, LiuPP, ParkerTG. S100B expression modulates left ventricular remodeling after myocardial infarction in mice. Circulation111 (5), 598–606 (2005).
   PubMed Web of Science ®Google Scholar
• Volkers M , RohdeD, GoodmanC, MostP. S100A1: a regulator of striated muscle sarcoplasmic reticulum Ca2+ handling, sarcomeric, and mitochondrial function. J. BioMed. Biotechnol.2010, 178614 (2010).
   PubMedGoogle Scholar
• Yamaguchi N , ChakrabortyA, HuangTQet al. Cardiac hypertrophy associated with impaired regulation of cardiac ryanodine receptor by calmodulin and S100A1. Am. J. Physiol. Heart Circ. Physiol.305 (1), H86–H94 (2013).
   PubMed Web of Science ®Google Scholar
• Most P , SeifertH, GaoEet al. Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction. Circulation114 (12), 1258–1268 (2006).
   PubMed Web of Science ®Google Scholar
• Hernandez-Ochoa EO , ProsserBL, WrightNT, ContrerasM, WeberDJ, SchneiderMF. Augmentation of Cav1 channel current and action potential duration after uptake of S100A1 in sympathetic ganglion neurons. Am. J. Physiol. Cell Physiol.297 (4), C955–C970 (2009).
   PubMed Web of Science ®Google Scholar
• Most P , RaakeP, WeberC, KatusHA, PlegerST. S100A1 gene therapy in small and large animals. Methods Mol. Biol.963, 407–420 (2013).
   PubMedGoogle Scholar
• Wang W , AspML, Guerrero-SernaG, MetzgerJM. Differential effects of S100 proteins A2 and A6 on cardiac Ca cycling and contractile performance. J. Mol. Cell Cardiol.72C, 117–125 (2014).
   Google Scholar
• Tamaki Y , IwanagaY, NiizumaSet al. Metastasis-associated protein, S100A4 mediates cardiac fibrosis potentially through the modulation of p53 in cardiac fibroblasts. J. Mol. Cell Cardiol.57, 72–81 (2013).
   PubMed Web of Science ®Google Scholar
• Wu Y , LiY, ZhangCet al. S100a8/a9 released by CD11b+Gr1+ neutrophils activates cardiac fibroblasts to initiate angiotensin II-induced cardiac inflammation and injury. Hypertension, 63 (6), 1241–1250 (2014).
   PubMed Web of Science ®Google Scholar
• Ehlermann P , EggersK, BierhausAet al. Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc. Diabetol.5, 6 (2006).
   PubMed Web of Science ®Google Scholar